58 filings
Page 3 of 3
8-K
yju ia2v0
30 Mar 22
Results of Operations and Financial Condition
7:40am
8-K
wp8bn l67rkdbdp
21 Mar 22
Departure of Directors or Certain Officers
6:32am
8-K/A
pjy11820xqfuh
21 Mar 22
Departure of Directors or Certain Officers
6:30am
8-K
yvu65u4vvi6tolhcywc
1 Mar 22
Departure of Directors or Certain Officers
5:07pm
8-K
s97akg9p6nq8n1x
23 Feb 22
Adagio Therapeutics Announces David Hering Appointed Interim Chief Executive Officer
5:07pm
8-K
jdc2no
22 Feb 22
Adagio Therapeutics Announces CEO Succession Plan
7:57am
8-K
2m9ea5z et
18 Feb 22
Departure of Directors or Certain Officers
5:29pm
8-K
3mdte0eanq
13 Jan 22
Regulation FD Disclosure
8:01am
8-K
c2dmnskmj
14 Dec 21
Adagio Therapeutics Reports Reduction in In Vitro Neutralizing Activity of ADG20 Against Omicron SARS-CoV-2 Variant
9:10am
8-K
2ch8 ao3olqivqmu321o
29 Nov 21
Regulation FD Disclosure
8:23am
8-K
tiusdzpgr4gc3aod
22 Nov 21
Adagio Therapeutics Announces Expansion of Management Team and Board of Directors
5:04pm
8-K
rz04lw769
16 Nov 21
Regulation FD Disclosure
5:24pm
8-K
vq35 zqs7dyn5q
15 Nov 21
Adagio Therapeutics Provides Update for ADG20 COVID-19 Antibody Program and Reports Third Quarter 2021 Financial Results
8:08am
8-K
cgzsxx rkntsu016gw5a
19 Oct 21
Adagio Therapeutics Announces New In Vitro Data Highlighting Broad and Potent Neutralization of ADG20 Against All Known SARS-CoV-2 Variants
4:03pm
8-K
risb8ces
29 Sep 21
Adagio Therapeutics Announces New Data Highlighting the Potential of ADG20 for Treatment and Prevention of COVID-19
4:41pm
8-K
2ek7ji
20 Sep 21
Adagio Therapeutics Provides COVID-19 Antibody Program Updates as well as Business
4:05pm
8-K
nrns3x
10 Sep 21
Adagio Therapeutics Announces Expansion of Patient Population in Global Phase 2/3 Clinical Trial of ADG20 for the Prevention of COVID-19
7:55am
8-K
ba9wo7j
10 Aug 21
Amendments to Articles of Incorporation or Bylaws
5:26pm